)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Cue Biopharma (CUE) investor relations material
Cue Biopharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Focused on developing Immuno-STAT® platform for autoimmune diseases and cancer, with lead programs CUE-401 (autoimmune), CUE-500 series (targeted cell depletion), and CUE-100 series (oncology).
Strategic collaborations with BI for CUE-501 (B cell depletion) and ImmunoScape for CUE-100 series and cell therapy for solid tumors, including $15M in upfront payments and a 40% equity stake in ImmunoScape.
Leadership transition: Usman Azam appointed CEO and President, Daniel Passeri transitioned to Strategic Advisor.
CUE-401 is engineered as a tolerogenic bifunctional molecule targeting immune tolerance in autoimmune diseases.
Financial highlights
Collaboration revenue was $2.1M for Q3 2025 (down from $3.3M in Q3 2024); net loss for Q3 2025 was $7.4M (improved from $8.7M in Q3 2024).
Cash, cash equivalents, and marketable securities totaled $11.7M as of September 30, 2025, down from $22.5M at year-end 2024.
R&D expenses for Q3 2025 were $4.8M (down from $9.4M), and for nine months: $21.2M (down from $29.1M in 2024).
General and administrative expenses for Q3 2025 rose to $4.9M from $2.9M, and for nine months: $12.8M (up from $10.6M), due to one-time severance and higher professional fees.
Net loss per share for Q3 2025: $(0.07); weighted average shares outstanding: 100.9M.
Outlook and guidance
Current cash and expected upfront payments from ImmunoScape are projected to fund operations into Q3 2026.
Additional capital will be required to continue operations beyond this period; plans include further equity offerings and strategic partnerships.
IND filing for CUE-401 planned for Q2 2026, with initial clinical data expected in H2 2026.
Future financing plans given going concern
Implications of CUE-101's 32.7-month mOS
ImmunoScape deal's strategic impact on pipeline
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cue Biopharma earnings date
Q4 202531 Mar, 2026
Next Cue Biopharma earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. The company is focused on developing its proprietary platform designed to modulate immune signaling with cytokine infiltration and inflammatory mediators to generate personalized therapeutic immunotherapies.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage